A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas

Trial Profile

A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Ewing's sarcoma; Osteosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2017 Planned number of patients changed from 64 to 90 as reported by ClinicalTrials.gov record.
    • 16 Aug 2017 Planned number of patients changed from 90 to 64 as reported by ClinicalTrials.gov record.
    • 16 Aug 2017 Planned primary completion date changed from 31 Jul 2017 to 30 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top